41052 Federal Register / Vol. 62, No. 147 / Thursday, July 31, 1997 / Notices

Antimicrobial Resistant Infections was

published in the Federal Register on

July 8, 1997, (62 FR 36541). The notice

is amended as follows:

On page 36543, under the heading

‘‘Specific Instructions,’’ second column,

4. Objectives and Technical Approach,

lines three and four have been changed

and should read: ‘‘Recipient Activities

(A.1.a., A.1.b., A.2., A.3., and

A.4.). . . .’’

On page 36544, second column, third

paragraph, c., line six should read

‘‘Activities A.4.). . . .’’

All other information and

requirements of the July 8, 1997,

Federal Register notice remain the

same.

Dated: July 25, 1997.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–20136 Filed 7–30–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members

on Public Advisory Committees; Blood

Products Advisory Committee

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is requesting

nominations to fill upcoming vacancies

on the Blood Products Advisory

Committee.

FDA has a special interest in ensuring

that women, minority groups, and

individuals with disabilities are

adequately represented on advisory

committees and, therefore, extends

particular encouragement to

nominations for appropriately qualified

female, minority, or disabled

candidates.

DATES: Nominations should be received

on or before August 15, 1997.

ADDRESSES: All nominations for

membership should be sent to the

appropriate contact person (address

below).

FOR FURTHER INFORMATION CONTACT:

All nominations and curricula vitae

except for consumer representatives

should be submitted in writing to

Linda A. Smallwood, Office of

Blood Research and Review (HFM–

350), Center for Biologics

Evaluation and Research, Food and

Drug Administration, 1401

Rockville Pike, Rockville, MD

20852–1448, 301–827–3514.

All nominations and curricula vitae

for consumer representatives

should be submitted in writing to

Annette J. Funn, Office of

Consumer Affairs (HFE–88), Food

and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–5006.

SUPPLEMENTARY INFORMATION: FDA is

requesting nominations to fill upcoming

vacancies on the Blood Products

Advisory Committee. The function of

the committee is to review and evaluate

available data concerning the safety,

effectiveness, appropriate use of blood

products derived from blood and serum

or biotechnology which are intended for

use in the diagnosis, prevention, or

treatment of human diseases, and, as

required, any other product for which

FDA has regulatory responsibility.

Persons nominated for membership

should be among authorities

knowledgeable in the fields of clinical

and administrative medicine, infectious

disease, hematology, immunology,

transfusion medicine, surgery, internal

medicine, biochemistry, biostatistics,

epidemiology, biological and physical

sciences, biotechnology, computer

technology, sociology/ethics, and other

related professions. The membership

will also include representatives of

consumer organizations, product

recipients, and health care providers.

The committee will function at times as

a medical device panel under the

Federal Food, Drug, and Cosmetic Act

Medical Device Amendments of 1976.

Nonvoting Consumer and Industry

Representation

Section 520(f)(3) of the Federal Food,

Drug, and Cosmetic Act (the act) (21

U.S.C. 360j(f)(3)), as amended by the

Medical Device Amendments of 1976,

provides that each medical device panel

include as members one nonvoting

representative of consumer interests and

one nonvoting representative of

interests of the manufacturing industry.

Nomination Procedures

Interested persons may nominate one

or more qualified persons for

membership on the committee. Self

nominations are also accepted. A

current curriculum vitae of each

nominee should accompany the letter of

nomination and include the following

information: Full name and title,

business address and phone number,

home address and phone number, date

and place of birth. Nominations shall

state that the nominee is willing to serve

as a member of the committee and

appears to have no conflict of interest

that would preclude advisory committee

membership. The Commissioner of

Food and Drugs will ask the potential

candidates to provide detailed

information concerning such matters as

financial holdings, consultancies, and

research grants or contracts to permit

evaluation of possible sources of

conflict of interest. The term of office

may not exceed 4 years, depending on

the appointment date.

The nomination procedures for the

nonvoting consumer representative and

industry representative are the same as

stated previously with the following

exceptions:

Consumer Representatives

To be eligible for selection, the

applicant’s experience and/or education

will be evaluated against Federal civil

service criteria for the position to which

the person will be appointed. The term

of office is up to 4 years.

Industry Representatives

Any organization representing

industry interests wishing to participate

in the selection of representatives may

nominate one or more qualified persons

to represent industry interests. Persons

who nominate themselves as industry

representatives will not participate in

the selection process. It is, therefore,

recommended that all nominations be

made by someone with an organization,

trade association, or firm who is willing

to participate in the selection process.

Nominees shall be full-time employees

of firms that manufacture products that

would come before the committee, or

consulting firms that represent

manufacturers. The term of office is up

to 4 years.

Selection Procedures

Consumer Representatives

Selection of members representing

consumers interests is conducted

through procedures which include use

of a consortium of consumer

organizations which has the

responsibility for recommending

candidates for the agency’s selection.

Candidates should possess appropriate

qualifications to understand and

contribute to the committee’s work.

Industry Representatives

Regarding nominations for members

representing the interests of industry, a

letter will be sent to each person that

has made a nomination, and to those

organizations indicating an interest in

participating in the selection process,

together with a complete list of all such

organizations and the nominees. This

letter will state that it is the

responsibility of each nominator or
Federal Register / Vol. 62, No. 147 / Thursday, July 31, 1997 / Notices 41053

organization indicating an interest in

participating in the selection process to

consult with the others in selecting a

single member representing industry

interests for the committee within 60

days after receipt of the letter. If no

individual is selected within 60 days,

the agency will select the nonvoting

member representing industry interests. This notice is issued under the

Federal Advisory Committee Act (5

U.S.C. app. 2), relating to advisory

committees.

Dated: July 24, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–20080 Filed 7-30-97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members

on Public Advisory Committees;

Science Board to the Food and Drug

Administration

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is requesting

nominations for members to serve on

the Science Board to the Food and Drug

Administration (the board) administered

from FDA’s Office of Science.

Nominations will be accepted for

upcoming vacancies that may or will

occur on the board during the next 24

months.

FDA has a special interest in ensuring

that women, minority groups, and

individuals with disabilities are

adequately represented on advisory

committees, and therefore, extends

particular encouragement to

nominations for appropriately qualified

female, minority, or physically disabled

candidates. Final selections from among

qualified candidates for each vacancy

will be determined by the expertise

required to meet specific agency needs

and in a manner to ensure appropriate

balance of membership.

DATES: All nominations must be

received by September 2, 1997.

ADDRESSES: All nominations for

membership and curricula vitae from

academia, industry, and government,

except for general public representatives

(consumer-nominated members), should

be sent to Susan K. Meadows (address

below). All nominations for general

public representatives (consumernominated members) should be sent to

Annette J. Funn (address below).

FOR FURTHER INFORMATION CONTACT:

Regarding all nominations for

membership, except for general

public representatives: Susan K.

Meadows, Office of Science (HF–

32), Food and Drug Administration,

5600 Fishers Lane, Rockville, MD

20857, 301–827–4591.

Regarding all nominations for general

public representatives: Annette J.

Funn, Office of Consumer Affairs

(HFE–88), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–

5006.

SUPPLEMENTARY INFORMATION: FDA is

requesting nominations for members to

serve on the board for upcoming

vacancies that may or will occur on the

board during the next 24 months.

Function

The function of the board is to

provide advice primarily to the agency’s

Senior Science Advisor and, as needed,

to the Commissioner of Food and Drugs

and other appropriate officials on

specific complex and technical issues as

well as emerging issues within the

scientific community in academia and

industry. Additionally, the board

provides advice to the agency on

keeping pace with technical and

scientific evolutions in the field of

regulatory science, on formulating an

appropriate research agenda and on

upgrading its scientific and research

facilities to keep pace with these

changes. The board also provides the

means for critical review of agencysponsored intramural and extramural

scientific research programs.

Criteria for Members

Persons nominated for membership

shall have exceptional accomplishments

and expertise in science, or executive

level experience in scientific

programmatic or laboratory management

involving scientific endeavors

appropriate to the work of the board and

the interests of FDA. Disciplines or

expertise of particular interest include

biomedical technology with application

to medical devices, biologics and

vaccine development and research, and

genetics. The term of office is 4 years.

General Public Representatives

(Consumer-nominated Members)

FDA currently attempts to place

members on advisory committees who

are nominated by consumer

organizations. These members are

recommended by a consortium of 12

consumer organizations that has the

responsibility for screening,

interviewing, and recommending

consumer-nominated candidates with

appropriate scientific credentials.

Candidates are sought who are aware of

the consumer impact of committee

issues, but who also possess enough

technical background to understand and

contribute to the committee’s work. The

agency notes, however, that for some

advisory committees, it may require

such nominees to meet the same

technical qualifications and specialized

training required of other expert

members of the committee. The term of

office for these members is up to 4

years, depending on the appointment

date. Nominations are invited for

consideration for membership as

openings become available.

Nomination Procedures

Any interested person may nominate

one or more qualified persons for

membership on the board. Nominations

shall state that the nominee is aware of

the nomination, is willing to serve as a

member of the board, and appears to

have no conflict of interest that would

preclude board membership. Potential

candidates will be asked by FDA to

provide detailed information concerning

such matters as financial holdings,

consultancies, and research grants or

contracts in order to permit evaluation

of possible sources of conflict of

interest.

This notice is issued under the

Federal Advisory Committee Act (5

U.S.C. app. 2) and 21 CFR part 14,

relating to advisory committees.

Dated: July 24, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–20082 Filed 7-30-97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F-0305]

Goldschmidt Chemical Corp.; Filing of

Food Additive Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Goldschmidt Chemical Corp. has

filed a petition proposing that the food

additive regulations be amended to

provide for the expanded safe use of

siloxanes and silicones; cetylmethyl,

dimethyl, methyl 11-methoxy-11-

oxoundecyl as a pigment dispersant in

all pigmented polymers intended for use

in contact with food.